Bisphosphonates for Breast Cancer: Questions Answered, Questions Remaining

Hematology/Oncology Clinics of North America

Volumn 21, Issue 2, 2007, Pages 341-367

  Layman, Rachel ^a   Olson, Karin ^b   Van Poznak, Catherine ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CARCINOMA; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; ESOPHAGITIS; FEVER; HUMAN; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VERTEBRA FRACTURE;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE MATRIX; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 34248576446     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.03.004     Document Type: Review

References (118)

1. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 5484 (2000) 1504-1508
2. Ganong W. Hormonal control of calcium metabolism and the physiology of bone. In: Foltin J., Lebowitz H., and Brown R.Y. (Eds). Review of medical physiology. 22nd edition (2005), Lange Medical Books/McGraw-Hill Medical Publishing Division, New York 382-395
3. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 16 (2004) 1655-1664
4. Russell R.G., Bisaz S., Fleisch H., et al. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet 2 7679 (1970) 899-902
5. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9 32 (2003) 2643-2658
6. Frith J.C., Monkkonen J., Auriola S., et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44 9 (2001) 2201-2210
7. Parfitt A.M. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55 3 (1994) 273-286
8. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 29 6 Suppl 21 (2002) 33-42
9. Green J.R. Antitumor effects of bisphosphonates. Cancer 97 3 Suppl (2003) 840-847
10. Vincenzi B., Santini D., Rocci L., et al. Bisphosphonates: new antiangiogenic molecules in cancer treatment?. Ann Oncol 14 5 (2003) 806-807
11. Coleman R.E. Skeletal complications of malignancy. Cancer 80 8 Suppl (1997) 1588-1594
12. Van Poznak C., and Nadal C. Bone integrity and bone metastases in breast cancer. Curr Oncol Rep 8 1 (2006) 22-28
13. Body J.J. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97 3 Suppl (2003) 859-865
14. Theriault R.L., Biermann J.S., Brown E., et al. NCCN Task Force Report: bone health and cancer care. J Natl Compr Canc Netw 4 Suppl 2 (2006) S1-S20 [quiz: S21-2]
15. Bauman G., Charette M., Reid R., et al. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol 75 3 (2005) 258-270
16. Robinson R.G., Preston D.F., Schiefelbein M., et al. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274 5 (1995) 420-424
17. Lane J.M., Hong R., Koob J., et al. Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Relat Res 426 (2004) 49-53
18. Saunders Y., Ross J.R., Broadley K.E., et al. Systematic review of bisphosphonates for hypercalcaemia of malignancy. Palliat Med 18 5 (2004) 418-431
19. Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 2 (2001) 558-567
20. Conte P.F., Latreille J., Mauriac L., et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 14 9 (1996) 2552-2559
21. Theriault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17 3 (1999) 846-854
22. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335 24 (1996) 1785-1791
23. Hortobagyi G.N., Theriault R.L., Lipton A., et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16 6 (1998) 2038-2044
24. Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88 5 (2000) 1082-1090
25. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 21 (2003) 4042-4057
26. Berenson J.R., Rosen L.S., Howell A., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 7 (2001) 1191-1200
27. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7 5 (2001) 377-387
28. Rosen L.S., Gordon D.H., Dugan Jr. W., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100 1 (2004) 36-43
29. Paterson A.H., Powles T.J., Kanis J.A., et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11 1 (1993) 59-65
30. Kristensen B., Ejlertsen B., Groenvold M., et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246 1 (1999) 67-74
31. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14 9 (2003) 1399-1405
32. Diel I.J., Body J.J., Lichinitser M.R., et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40 11 (2004) 1704-1712
33. Tripathy D., Lichinitzer M., Lazarev A., et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15 5 (2004) 743-750
34. Body J.J., Diel I.J., Lichinitzer M., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90 6 (2004) 1133-1137
35. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94 6 (1993) 646-650
36. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 6 (2001) 785-795
37. Cummings S.R., Bates D., and Black D.M. Clinical use of bone densitometry: scientific review. JAMA 288 15 (2002) 1889-1897
38. Rosen C.J. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353 6 (2005) 595-603
39. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva, Switzerland: World Health Organization; 1994. p. 1--129.
40. Raisz L.G. Clinical practice. Screening for osteoporosis. N Engl J Med 353 2 (2005) 164-171
41. Sambrook P., and Cooper C. Osteoporosis. Lancet 367 9527 (2006) 2010-2018
42. Cummings S.R., Karpf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 4 (2002) 281-289
43. Garnero P., Hausherr E., Chapuy M.C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11 10 (1996) 1531-1538
44. Sornay-Rendu E., Munoz F., Garnero P., et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20 10 (2005) 1813-1819
45. Kanis J.A., McCloskey E.V., Powles T., et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79 7-8 (1999) 1179-1181
46. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005) 2747-2757
47. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
48. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 17 (2005) 1262-1271
49. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 9484 (2005) 455-462
50. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
51. Boccardo F., Rubagotti A., Guglielmini P., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17 Suppl 7 (2006) vii10-vii14
52. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 3 (2005) 619-629
53. McCloskey E., Hannon R., Lakner G., et al. The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: a direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women. J Clin Oncol 24 18S (2006) 16s
54. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
55. Coleman R.E. Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24 18S (2006) 5s
56. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
57. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24 22 (2006) 3629-3635
58. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 13 (1992) 852-856
59. Powles T.J., Hickish T., Kanis J.A., et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 1 (1996) 78-84
60. Vehmanen L., Elomaa I., Blomqvist C., et al. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 24 4 (2006) 675-680
61. Klijn J.G., Blamey R.W., Boccardo F., et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19 2 (2001) 343-353
62. Sverrisdottir A., Fornander T., Jacobsson H., et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22 18 (2004) 3694-3699
63. Gnant M., Jakesz R., Mlineritsch B., et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen-bone density subprotocol results of a randomized multicenter trial (ABCSG-12). [abstract 6]. Breast Cancer Res Treat 88 Suppl 1 (2004) S8-S9
64. Bines J., Oleske D.M., and Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14 5 (1996) 1718-1729
65. Goodwin P.J., Ennis M., Pritchard K.I., et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17 8 (1999) 2365-2370
66. Fornier M.N., Modi S., Panageas K.S., et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104 8 (2005) 1575-1579
67. Shapiro C.L., Manola J., and Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19 14 (2001) 3306-3311
68. Vehmanen L., Saarto T., Elomaa I., et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37 18 (2001) 2373-2378
69. Greep N.C., Giuliano A.E., Hansen N.M., et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114 8 (2003) 653-659
70. Rodriguez-Rodriguez L.M., Rodriguez-Rodriguez E.M., Oramas-Rodriguez J.M., et al. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer. Breast Cancer Res Treat 93 1 (2005) 75-83
71. Gass M., and Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 119 4 Suppl 1 (2006) S3-S11
72. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 9041 (1996) 1535-1541
73. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 22 (1995) 1437-1443
74. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 24 (1998) 2077-2082
75. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282 14 (1999) 1344-1352
76. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 1 (2000) 83-91
77. Chesnut I.C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 8 (2004) 1241-1249
78. Heikkinen J.E., Selander K.S., Laitinen K., et al. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res 12 1 (1997) 103-110
79. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 9 (2002) 653-661
80. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290 13 (2003) 1729-1738
81. Banks E., Beral V., Reeves G., et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291 18 (2004) 2212-2220
82. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
83. Holmberg L., and Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 363 9407 (2004) 453-455
84. Ramaswamy B., and Shapiro C.L. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 30 6 (2003) 763-775
85. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 7 (1999) 637-645
86. Delmas P.D., Ensrud K.E., Adachi J.D., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 8 (2002) 3609-3617
87. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 2 (2006) 125-137
88. Zujewski J., Eng-Wong J., Reynolds J., et al. A phase 2 trial of raloxifene in premenopausal women at high risk for developing invasive breast cancer. [abstract 417]. Breast Cancer Res Treat 76 Suppl 1 (2002) S108
89. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 9 (2001) 684-690
90. Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 23 (2004) 1751-1761
91. O'Regan R.M., Gajdos C., Dardes R.C., et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 94 4 (2002) 274-283
92. Chesnut III C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109 4 (2000) 267-276
93. Hodsman A.B., Bauer D.C., Dempster D.W., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26 5 (2005) 688-703
94. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 19 (2001) 1434-1441
95. Vahle J.L., Sato M., Long G.G., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30 3 (2002) 312-321
96. Hoey R.P., Sanderson C., Iddon J., et al. The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer 88 4 (2003) 567-573
97. Delmas P.D., Balena R., Confravreux E., et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15 3 (1997) 955-962
98. Fuleihan G.E., Salamoun M., Mourad Y.A., et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90 6 (2005) 3209-3214
99. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 33 2 Suppl 7 (2006) S13-S17
100. Jaschke A, Bastert G; Solomayer EF; et-al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a longtime follow-up. J Clin Orthod, 2004 ASCO Annual Meeting Proceedings (Post-meeting Edition). 2004;22(14S):529.
101. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 8 2 (2006) R13
102. Saarto T., Vehmanen L., Virkkunen P., et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43 7 (2004) 650-656
103. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 Suppl 4 (2004) 28-37
104. Tanvetyanon T., and Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17 6 (2006) 897-907
105. Balla J. The issue of renal safety of zoledronic acid from a nephrologist's point of view. Oncologist 10 5 (2005) 306-308 [author reply 311-2]
106. Chang J.T., Green L., and Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 349 17 (2003) 1676-1679 [discussion: 1676-79]
107. Markowitz G.S., Appel G.B., Fine P.L., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12 6 (2001) 1164-1172
108. Markowitz G.S., Fine P.L., Stack J.I., et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64 1 (2003) 281-289
109. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 10 (2006) 753-761
110. American Dental Association Council on Scientific Affairs. Expert panel recommendations: dental management of patients on oral bisphosphonate therapy. J Am Dent Assoc 137 8 (2006) 1144-1150
111. Ruggiero S., Gralow J., Marx R., et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice 2 1 (2006) 7-14
112. Macarol V., and Fraunfelder F.T. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118 2 (1994) 220-224
113. Coleman R.E. Bisphosphonates in breast cancer. Ann Oncol 16 5 (2005) 687-695
114. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 3 (2001) 165-176
115. Giordano S.H., Buzdar A.U., Smith T.L., et al. Is breast cancer survival improving?. Cancer 100 1 (2004) 44-52
116. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 22 (2005) 4925-4935
117. Lipton A., Hei Y., Coleman R., et al. Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer. [abstract 3015]. Breast Cancer Res Treat 94 Suppl 1 (2005) S129
118. Shupnik M.A. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23 48 (2004) 7979-7989